HC Wainwright Reiterates Buy Rating on Crescent Biopharma, Keeps $36 Target
HC Wainwright reiterated its Buy rating and $36 price target on Crescent Biopharma. The target implies 204.1% upside from the Oct. 16 close of $11.84.
Story updates
10:29:42 AM UTC
SquawkNews
Crescent Biopharma Price Target Maintained With a $36.00/Share by HC Wainwright & Co.